IDEXX (IDXX) EVP Michael Erickson exercises options and sells 5,371 shares
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
IDEXX Laboratories Executive Vice President Michael G. Erickson reported multiple stock option exercises and related share sales. On February 17, 2026 and February 19, 2026, he exercised incentive and non-qualified stock options and received IDEXX common shares.
On February 17, 2026, he then sold 5,371 shares of common stock in open-market transactions at weighted average prices ranging from about $623.28 to $629.8625 per share. After these transactions, he directly held 12,693.351 shares of IDEXX common stock, including 184 vested but deferred restricted stock units.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Seller: 5,371 shares ($3,369,666)
Net Sell
20 txns
Insider
Erickson Michael G
Role
Executive Vice President
Sold
5,371 shs ($3.37M)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Incentive Stock Option (right-to-buy) | 719 | $0.00 | -- |
| Exercise | Incentive Stock Option (right-to-buy) | 817 | $0.00 | -- |
| Exercise | Incentive Stock Option (right-to-buy) | 483 | $0.00 | -- |
| Exercise | Incentive Stock Option (right-to-buy) | 183 | $0.00 | -- |
| Exercise | Incentive Stock Option (right-to-buy) | 197 | $0.00 | -- |
| Exercise | Common Stock | 719 | $141.60 | $102K |
| Exercise | Common Stock | 817 | $178.26 | $146K |
| Exercise | Common Stock | 483 | $206.94 | $100K |
| Exercise | Common Stock | 183 | $544.08 | $100K |
| Exercise | Common Stock | 197 | $505.53 | $100K |
| Exercise | Non-Qualified Stock Option (right-to-buy) | 1,191 | $0.00 | -- |
| Exercise | Non-Qualified Stock Option (right-to-buy) | 4,180 | $0.00 | -- |
| Exercise | Common Stock | 1,191 | $141.60 | $169K |
| Exercise | Common Stock | 4,180 | $178.26 | $745K |
| Sale | Common Stock | 456 | $623.7582 | $284K |
| Sale | Common Stock | 204 | $625.2423 | $128K |
| Sale | Common Stock | 1,288 | $626.2564 | $807K |
| Sale | Common Stock | 2,694 | $628.2208 | $1.69M |
| Sale | Common Stock | 689 | $629.0906 | $433K |
| Sale | Common Stock | 40 | $629.8625 | $25K |
Holdings After Transaction:
Incentive Stock Option (right-to-buy) — 0 shares (Direct);
Common Stock — 13,412.351 shares (Direct);
Non-Qualified Stock Option (right-to-buy) — 0 shares (Direct)
Footnotes (1)
- Represents the weighted average price of the shares sold ranging from a low of $623.28 to a high of $624.27 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Represents the weighted average price of the shares sold ranging from a low of $624.89 to a high of $625.56 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Represents the weighted average price of the shares sold ranging from a low of $626.045 to a high of $628.38 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Represents the weighted average price of the shares sold ranging from a low of $627.74 to a high of $628.67 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Represents the weighted average price of the shares sold ranging from a low of $628.755 to a high of $629.615 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Includes 184 vested but deferred restricted stock units. Grant of option to buy shares of Issuer common stock that vested in five annual installments beginning on February 14, 2018. Grant of option to buy shares of Issuer common stock that vested in five annual installments beginning on February 14, 2019. Grant of option to buy shares of Issuer common stock that vested in one installment on February 14, 2022. Grant of option to buy shares of Issuer common stock that vested in one installment on February 14, 2023. Grant of option to buy shares of Issuer common stock that vested in one installment on February 14, 2024. Grant of option to buy shares of Issuer common stock that vested in one installment on February 14, 2025. Grant of option to buy shares of Issuer common stock that vested in one installment on February 14, 2026.
FAQ
What insider transactions did IDEXX (IDXX) executive Michael Erickson report?
Michael G. Erickson reported exercising multiple stock options and selling IDEXX common shares. He completed several option exercises that delivered common stock, then sold 5,371 shares in open-market trades at weighted average prices between $623.28 and $629.8625 per share.
What types of equity awards did Michael Erickson exercise in IDEXX (IDXX)?
Erickson exercised both incentive stock options and non-qualified stock options for IDEXX common stock. These options were granted under prior awards that vested in annual or single installments on various February 14 vesting dates from 2018 through 2026, according to the option grant footnotes.
Were Michael Erickson’s IDEXX (IDXX) stock sales reported as open-market transactions?
Yes, the sales were reported with transaction code “S,” indicating open-market or private sales of common stock. Footnotes show each sale’s weighted average price and confirm the company can provide full details about the number of shares sold at each separate price level.